Combined antidepressant and hormone treatment is effective for chemotherapy-induced menopausal syndrome.
Lin
Yi-Hsiung
YH
Department of Psychiatry, Chang Gung Medical Center, Kuei-San, Tao-Yuan, Taiwan.
Liu
Chia-Yih
CY
Hsiao
Mei-Chun
MC
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use; D003511:Cyclohexanols / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D064420:Drug-Related Side Effects and Adverse Reactions; D004967:Estrogens / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008594:Menopause, Premature / Q000097:blood / Q000187:drug effects* / Q000523:psychology*; D016584:Panic Disorder / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003280:Contraceptives, Oral, Synthetic; D003511:Cyclohexanols; D004967:Estrogens; D000069470:Venlafaxine Hydrochloride; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone